Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- PANACEABIO.NSE
- Price
- 357.15
- Stock movement down
- -6.10 (-1.68%)
- Company name
- Panacea Biotec Limited
- Exchange
- (NSE ,
- Currency
- INR )
- Sector
- Healthcare >Biotechnology
- Market cap
- 21.88B
- Ent value
- 25.52B
- Price/Sales
- 3.62
- Price/Book
- 2.65
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -46.30%
- 1 year return
- -23.56%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-12-15
DIVIDENDS
PANACEABIO.NSE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | 45.01 |
| EV to EBITDA | 52.51 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3.62 |
| Price to Book | 2.65 |
| EV to Sales | 4.23 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 61.25M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 636.70M |
| Net receivables | 762.20M |
| Total current assets | 5.33B |
| Goodwill | 0.00 |
| Intangible assets | 455.40M |
| Property, plant and equipment | 6.43B |
| Total assets | 12.54B |
| Accounts payable | 1.85B |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 3.45B |
| Total liabilities | 4.28B |
| Shareholder's equity | 8.26B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 361.60 |
| Daily high | 374.00 |
| Daily low | 353.50 |
| Daily Volume | 114K |
| All-time high | 566.20 |
| 1y analyst estimate | 69.00 |
| Beta | 0.29 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | 19 Sep 2011 |
| Next earnings date | 12 Feb 2026 |
Downside potential
Loading...
Downside potential data
| PANACEABIO.NSE | S&P500 | |
| Current price drop from All-time high | -36.92% | -1.22% |
| Highest price drop | -42.28% | -19.00% |
| Date of highest drop | 8 Dec 2025 | 8 Apr 2025 |
| Avg drop from high | -21.64% | -2.64% |
| Avg time to new high | 50 days | 6 days |
| Max time to new high | 152 days | 89 days |
COMPANY DETAILS
Marketcap
21.88B
Marketcap category
Large-cap
Description
Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. It operates through Vaccines and Pharmaceutical formulations & Nutrition segments. The company's product portfolio includes prescription products in various therapeutic areas, such as oncology, diabetes, gastro-intestinal care, nephrology, orthopedics, pain management, and fever; cold and cough; and betacoronavirus, SARS-CoV-2, typhoid conjugate, pneumococcal conjugate, tetravalent dengue, Mpox, and hepatitis A vaccines etc. It also offers health supplement products; and paediatric nutrition products under the ChilRunFull, ChilRun 7+, and ChillRun No Sucrose brands. In addition, the company engages in the real estate business. It exports its products to approximately 50 countries. The company has collaboration agreements with the Russian Direct Investment Fund for producing Covid-19 vaccine, and Sputnik-V; and the Indian Council of Medical Research for clinical trials of DengiAll vaccine. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.
Employees
2149
Investor relations
-
SEC filings
CEO
Country
India
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found